Analyst firms · H.C. Wainwright · KRRO

H.C. Wainwright KRRO price target and rating history

Korro Bio Inc. (KRRO) · Health Care

H.C. Wainwright rates Korro Bio Inc. (KRRO) Buy with a $20 price target, as of its latest action on Jan 29, 2026. It has published 4 rating actions on KRRO since December 2023, including 1 upgrade and 1 downgrade. Across 7 firms with a KRRO price target in the last 12 months, the median target is $21. H.C. Wainwright's $20 is 5% below that.

Current rating
Buy
Price target
$20
Median target, all firms
$21
Actions on KRRO
4

H.C. Wainwright price target on KRRO

$115$68$20202420252026
H.C. Wainwright price target on KRRO, each point a stated target, December 2023 to January 2026.

Every H.C. Wainwright rating on KRRO

How other firms rate KRRO

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
CitigroupBuy$21May 18, 2026
Raymond JamesOutperform$23Mar 13, 2026
William BlairOutperformFeb 17, 2026
Piper SandlerOverweight$30Jan 29, 2026
Chardan Capital MarketsBuy$15Jan 29, 2026
H.C. WainwrightBuy$20Jan 29, 2026
Cantor FitzgeraldOverweight$21Jan 28, 2026
OppenheimerOutperform$22Jan 28, 2026

Questions about H.C. Wainwright and KRRO

What is H.C. Wainwright's price target for KRRO?
H.C. Wainwright's latest stated price target for Korro Bio Inc. (KRRO) is $20, from its action on Jan 29, 2026.
What is H.C. Wainwright's rating on KRRO?
H.C. Wainwright rates KRRO Buy, a bullish rating, as of Jan 29, 2026.
When did H.C. Wainwright last change its view on KRRO?
On Jan 29, 2026, H.C. Wainwright upgrades to Buy from Neutral, price target $20.
How does H.C. Wainwright's KRRO target compare with other analysts?
Across 7 firms with a KRRO price target in the last 12 months, the median target is $21. H.C. Wainwright's $20 is 5% below that.

More KRRO rating histories

All H.C. Wainwright ratingsKRRO news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.